The effectiveness of once-daily subcutaneous liraglutide administration for weight loss management in adults was established in five large-scale randomized multicentre phase 3 trials [49,50,51,52,53], four of which were part of the SCALE program (Satiety and Clinical AdiposityLiraglutide Evidence in nondiabetic and diabetic individuals), leading to its approval at a dose of 3.0 mg subcutaneous once-daily (weekly increased from 0.6 mg to 3 mg/day)
The National Institute on Drug Abuse (NIDA) is currently funding randomized clinical studies to assess whether GLP-1 medications could help treat opioid and stimulant use disorders as well
As is common in drug research, initial trials of GLP-1s excluded people who said they were planning to conceive, but that population still uses these medications
Is there really a shortage
Statistical Method All statistical analysis in the manuscript were done using Graphpad prism Unpaired t- test
These are young men who describe themselves as involuntarily celibate